Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by nine senior executives and directors on August 9, 2013. The transactions occurred at a price of 1,663.38 pence per share. Each individual acquired shares through two components: a personal contribution element and a matching company contribution element.
- Sir Andrew Witty: Acquired 8 shares (personal) and 8 shares (company match).
- Mr S Dingemans: Acquired 8 shares (personal) and 8 shares (company match).
- Mr S M Bicknell: Acquired 8 shares (personal) and 8 shares (company match).
- Mr R G Connor: Acquired 8 shares (personal) and 8 shares (company match).
- Mr D S Redfern: Acquired 8 shares (personal) and 8 shares (company match).
- Ms C Thomas: Acquired 8 shares (personal) and 8 shares (company match).
- Mr P C Thomson: Acquired 7 shares (personal) and 7 shares (company match).
- Dr P J T Vallance: Acquired 8 shares (personal) and 8 shares (company match).
- Ms E Walmsley: Acquired 8 shares (personal) and 8 shares (company match).
- Mrs V A Whyte: Acquired 8 shares (personal) and 8 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,663.38 pence per Ordinary Share on August 9, 2013.
- Confirm the total number of shares acquired by each listed director under the ShareReward Plan.
- Note that this filing contains no financial performance metrics for the period.